Host restriction of HIV-1 by APOBEC3 and viral evasion through Vif

Current Topics in Microbiology and Immunology

Volumn 339, Issue 1, 2009, Pages 1-25

  Niewiadomska, Anna Maria ^a   Yu, Xiao Fang ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 1; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 2; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3A; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3B; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3C; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3DE; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3H; CYTIDINE DEAMINASE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VIF PROTEIN; APOBEC3 PROTEIN, HUMAN; CYTOSINE DEAMINASE; PROTEASOME; VIF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIVIRAL ACTIVITY; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CELL CYCLE ARREST; CRYSTAL STRUCTURE; DEAMINATION; DNA PACKAGING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DNA INTERACTION; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; PROTEIN STRUCTURE; RETROPOSON; REVERSE TRANSCRIPTION; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; SOMATIC HYPERMUTATION; VIRION; VIRUS INFECTIVITY; VIRUS MUTATION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; CELL CYCLE; IMMUNE RESPONSE; PHYSIOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1; PRIMATES;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CELL CYCLE; CYTOSINE DEAMINASE; HIV-1; HUMANS; IMMUNE EVASION; PROTEASOME ENDOPEPTIDASE COMPLEX; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77950487440     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-02175-6_1     Document Type: Review

References (177)

1. Aguiar RS et al (2008) Vpr.A3A chimera inhibits HIV replication. J Biol Chem 283(5):2518-2525
2. Alce TM, Popik W (2004) APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J Biol Chem 279(33):34083-34086
3. Anderson JL, Hope TJ (2008) APOBEC3G restricts early HIV-1 replication in the cytoplasm of target cells. Virology 375(1):1-12
4. Bach D et al (2008) Characterization of APOBEC3G binding to 7SL RNA. Retrovirology 5:54
5. Barnes DE, Lindahl T (2004) Repair and genetic consequences of endogenous DNA base damage in mammalian cells. Annu Rev Genet 38:445-476
6. Baumert TF et al (2007) Hepatitis B virus DNA is subject to extensive editing by the human deaminase APOBEC3C. Hepatology 46(3):683-689
7. Bernardi R, Pandolfi PP (2007) Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol 8(12):1006-1016
8. Bieniasz PD (2004) Intrinsic immunity: a front-line defense against viral attack. Nat Immunol 5 (11):1109-1115
9. Billich A et al (1995) Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: interference with HIV protein-cyclophilin A interactions. J Virol 69(4):2451-2461
10. Bishop KN et al (2004) Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol 14(15):1392-1396
11. Bishop KN, Holmes RK, Malim MH (2006) Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J Virol 80(17):8450-8458
12. Bishop KN et al (2008) APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog 4(12):e1000231
13. Bogerd HP et al (2004) A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci USA 101 (11):3770-3774
14. Bogerd HP et al (2006a) Cellular inhibitors of long interspersed element 1 and Alu retrotransposi-tion. Proc Natl Acad Sci USA 103(23):8780-8785
15. Bogerd HP et al (2006b) APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotran-sposon function in human cells. Nucleic Acids Res 34(1):89-95
16. Bonvin M et al (2006) Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 43(6):1364-1374
17. Burnett A, Spearman P (2007) APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-depen-dent process requiring the NC basic linker. J Virol 81(10):5000-5013
18. Cai H et al (1993) Kinetics of deoxyribonucleotide insertion and extension at abasic template lesions in different sequence contexts using HIV-1 reverse transcriptase. J Biol Chem 268 (231):23567-23572
19. Cen S et al (2004) The interaction between HIV-1 Gag and APOBEC3G. J Biol Chem 279 (32):33177-33184
20. Chang AH, O'Shaughnessy MV, Jirik FR (2001) Hck SH3 domain-dependent abrogation of Nef-induced class 1 MHC down-regulation. Eur J Immunol 31(8):2382-2387
21. Chen H et al (2006) APOBEC3A is a potent inhibitor of adeno-associated virus and retrotranspo-sons. Curr Biol 16(5):480-485
22. Chen KM et al (2008) Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature 452(7183):116-119
23. Chiu YL, Greene WC (2008) The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu Rev Immunol 26:317-353
24. Chiu YL et al (2005) Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 435(7038):108-114
25. Chiu YL et al (2006) High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc Natl Acad Sci USA 103(42):15588-15593
26. Conticello SG, Harris RS, Neuberger MS (2003) The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol 13(22):2009-2013
27. Conticello SG et al (2005) Evolution of the AID/APOBEC family of polynucleotide (deoxy) cytidine deaminases. Mol Biol Evol 22(2):367-377
28. Dang Y et al (2006) Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J Virol 80(21):10522-10533
29. Dehart JL et al (2007) HIV-1 Vpr activates the G2 checkpoint through manipulation of the ubiquitin proteasome system. Virol J 4(1):57
30. DeHart JL et al (2008) Human immunodeficiency virus type 1 Vif induces cell cycle delay via recruitment of the same E3 ubiquitin ligase complex that targets APOBEC3 proteins for degradation. J Virol 82(18):9265-9272
31. Derse D et al (2007) Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid. Proc Natl Acad Sci USA 104(8):2915-2920
32. Douaisi M et al (2004) HIV-1 and MLV Gag proteins are sufficient to recruit APOBEC3G into virus-like particles. Biochem Biophys Res Commun 321(3):566-573
33. Dutko JA et al (2005) Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases. Curr Biol 15(7):661-666
34. Esnault C et al (2006) Dual inhibitory effects of APOBEC family proteins on retrotransposition of mammalian endogenous retroviruses. Nucleic Acids Res 34(5):1522-1531
35. Furukawa A et al (2009) Structure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3G. Embo J 28(4):440-451
36. Gabuzda DH et al (1992) Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol 66(11):6489-6495
37. Goff SP (2003) Death by deamination: a novel host restriction system for HIV-1. Cell 114 (3):281-283
38. Goila-Gaur R, Strebel K (2008) HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 5:51
39. Goila-Gaur R et al (2008) HIV-1 Vif promotes the formation of high molecular mass APOBEC3G complexes. Virology 372(1):136-146
40. Guo F et al (2006) Inhibition of formula-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J Virol 80(23):11710-11722
41. Guo F, et al. (2007) The interaction of APOBEC3G with HIV-1 nucleocapsid inhibits tRNALys3 annealing to viral RNA. J Virol doi:10.1128/JVI.00162-07
42. Hache G, Liddament MT, Harris RS (2005) The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J Biol Chem 280(12):10920-10924
43. Harris RS, Liddament MT (2004) Retroviral restriction by APOBEC proteins. Nat Rev Immunol 4 (11):868-877
44. Harris RS, Petersen-Mahrt SK, Neuberger MS (2002) RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol Cell 10(5):1247-1253
45. Harris RS et al (2003) DNA deamination mediates innate immunity to retroviral infection. Cell 113(6):803-809
46. Hassaine G et al (2001) The tyrosine kinase Hck is an inhibitor of HIV-1 replication counteracted by the viral vif protein. J Biol Chem 276(20):16885-16893
47. He J et al (1995) Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 69(11):6705-6711
48. He Z et al (2008) Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J Mol Biol 381(4):1000-1011
49. Holden LG et al (2008) Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature 456(7218):121-124
50. Holmes RK et al (2007) APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J Biol Chem 4:2587-2595
51. Huthoff H, Malim MH (2007) Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and virion encapsidation. J Virol 81(8):3807-3815
52. Iwatani Y et al (2006) Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J Virol 80(12):5992-6002
53. Iwatani Y et al (2007) Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res 35(21):7096-7108
54. Jarmuz A et al (2002) An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79(3):285-296
55. Jost S et al (2007) Induction of antiviral cytidine deaminases does not explain the inhibition of hepatitis B virus replication by interferons. J Virol 81(19):10588-10596
56. Jowett JB et al (1995) The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J Virol 69(10):6304-6313
57. Kaiser SM, Emerman M (2006) Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G. J Virol 80(2):875-882
58. Kan NC et al (1986) Identification of HTLV-III/LAV sor gene product and detection of antibodies in human sera. Science 231(4745):1553-1555
59. Kao S et al (2007) Production of infectious virus and degradation of APOBEC3G are separable functional properties of human immunodeficiency virus type 1 Vif. Virology 369(2):329-339
60. Khan MA et al (2005) Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J Virol 79(9):5870-5874
61. Khan MA et al (2007) Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions. Retrovirology 4:48
62. Klarmann GJ et al (2003) Incorporation of uracil into minus strand DNA affects the specificity of plus strand synthesis initiation during lentiviral reverse transcription. J Biol Chem 278 (10):7902-7909
63. Kobayashi M et al (2004) APOBEC3G targets specific virus species. J Virol 78(15):8238-8244
64. Kobayashi M et al (2005) Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C complex is essential for Vif function. J Biol Chem 280(19):18573-18578
65. Kreisberg JF, Yonemoto W, Greene WC (2006) Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation. J Exp Med 203(4):865-870
66. Langlois MA, Neuberger MS (2008) Human APOBEC3G can restrict retroviral infection in avian cells and acts independently of both UNG and SMUG1. J Virol 82(9):4660-4664
67. Lecossier D et al (2003) Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300(5622):1112
68. Lee YN, Bieniasz PD (2007) Reconstitution of an infectious human endogenous retrovirus. PLoS Pathog 3(1):e10
69. Lee TH et al (1986) A new HTLV-III/LAV protein encoded by a gene found in cytopathic retroviruses. Science 231(4745):1546-1549
70. Lee B et al (1999) Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci USA 96(9):5215-5220
71. Lee YN, Malim MH, Bieniasz PD (2008) Hypermutation of an ancient human retrovirus by APOBEC3G. J Virol 82(17):8762-8770
72. Li L et al (2001) Role of the non-homologous DNA end joining pathway in the early steps of retroviral infection. Embo J 20(12):3272-3281
73. Li XY et al (2007) APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. J Biol Chem 282(44):32065-32074
74. Liao W et al (1999) APOBEC-2, a cardiac-and skeletal muscle-specific member of the cytidine deaminase supergene family. Biochem Biophys Res Commun 260(2):398-404
75. Liddament MT et al (2004) APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol 14(15):1385-1391
76. Liu B et al (2004) Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J Virol 78(4):2072-2081
77. Liu B et al (2005) Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. J Virol 79(15):9579-9587
78. Luo K et al (2004) Amino-terminal region of the human immunodeficiency virus type 1 nucleo-capsid is required for human APOBEC3G packaging. J Virol 78(21):11841-11852
79. Luo K et al (2005) Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc Natl Acad Sci USA 102(32):11444-11449
80. Luo K et al (2007) Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J Virol 81 (13):7238-7248
81. Madani N, Kabat D (1998) An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J Virol 72(12):10251-10255
82. Madani N et al (2002) Implication of the lymphocyte-specific nuclear body protein Sp140 in an innate response to human immunodeficiency virus type 1. J Virol 76(21):11133-11138
83. Mahieux R et al (2005) Extensive editing of a small fraction of human T-cell leukemia virus type 1 genomes by four APOBEC3 cytidine deaminases. J Gen Virol 86(Pt 9):2489-2494
84. Mangeat B et al (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424(6944):99-103
85. Mangeat B et al (2004) A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J Biol Chem 279(15):14481-14483
86. Mansky LM et al (2000) The interaction of vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 In vivo mutation rate. J Virol 74(15):7039-7047
87. Mariani R et al (2003) Species-Specific Exclusion of APOBEC3G from HIV-1 Virions by Vif. Cell 114(1):21-31
88. Marin M et al (2003) HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 9(11):1398-1403
89. Marin M et al (2008) Human immunodeficiency virus type 1 Vif functionally interacts with diverse APOBEC3 cytidine deaminases and moves with them between cytoplasmic sites of mRNA metabolism. J Virol 82(2):987-998
90. Mbisa JL et al (2007) Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol 81 (13):7099-7110
91. Mehle A et al (2004) Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev 18(23):2861-2866
92. Mehle A et al (2006) A zinc-binding region in Vif binds Cul5 and determines cullin selection. J Biol Chem 281(25):17259-17265
93. Mehle A et al (2007) Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J Virol 81(23):13235-13241
94. Mikl MC et al (2005) Mice deficient in APOBEC2 and APOBEC3. Mol Cell Biol 25 (16):7270-7277
95. Miyagi E et al (2007) Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J Virol 81(24):13346-13353
96. Muckenfuss H et al (2006) APOBEC3 proteins inhibit human LINE-1 retrotransposition. J Biol Chem 281(31):22161-22172
97. Navarro F, Landau NR (2004) Recent insights into HIV-1 Vif. Curr Opin Immunol 16(4):477-482
98. Navarro F et al (2005) Complementary function of the two catalytic domains of APOBEC3G. Virology 333(2):374-386
99. Newman EN et al (2005) Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol 15(2):166-170
100. Nguyen DH, Gummuluru S, Hu J (2007) Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G. J Virol 81(9):4465-4472
101. Niewiadomska AM et al (2007) Differential inhibition of long interspersed element 1 by APO-BEC3 does not correlate with high-molecular-mass-complex formation or P-body association. J Virol 81(17):9577-9583
102. Noguchi C et al (2005) G to A hypermutation of hepatitis B virus. Hepatology 41(3):626-33
103. OhAinle M et al (2008) Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe 4(3):249-259
104. Ohsugi T, Koito A (2007) Human T cell leukemia virus type I is resistant to the antiviral effects of APOBEC3. J Virol Methods 139(1):93-96
105. Onafuwa-Nuga AA, Telesnitsky A, King SR (2006) 7SL RNA, but not the 54-kd signal recognition particle protein, is an abundant component of both infectious HIV-1 and minimal viruslike particles. Rna 12(4):542-546
106. Opi S et al (2007) Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. J Virol 81(15):8236-8246
107. Pickart CM (2004) Back to the future with ubiquitin. Cell 116(2):181-190
108. Priet S et al (2003) Differential incorporation of uracil DNA glycosylase UNG2 into HIV-1, HIV-2, and SIV(MAC) viral particles. Virology 307(2):283-289
109. Rogozin IB et al (2005) APOBEC4, a new member of the AID/APOBEC family of polynucleotide (deoxy) cytidine deaminases predicted by computational analysis. Cell Cycle 4(9):1281-1285
110. Rose KM et al (2004) Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus. J Biol Chem 279(40):41744-41749
111. Rosler C et al (2005) APOBEC-mediated interference with hepadnavirus production. Hepatology 42(2):301-309
112. Russell RA, Pathak VK (2007) Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol 81 (15):8201-8210
113. Russell RA et al (2008) Distinct domains within apobec3g and apobec3f interact with separate regions of hiv-1 Vif. J Virol 83(4):1992-2003
114. Sakai K, Dimas J, Lenardo MJ (2006) The Vif and Vpr accessory proteins independently cause HIV-1-induced T cell cytopathicity and cell cycle arrest. Proc Natl Acad Sci USA 103(9):3369-3374
115. Saksela K, Cheng G, Baltimore D (1995) Proline-rich (PxxP) motifs in HIV-1 Nef bind to SH3 domains of a subset of Src kinases and are required for the enhanced growth of Nef+ viruses but not for down-regulation of CD4. Embo J 14(3):484-491
116. Santa-Marta M et al (2004) HIV-1 Vif can directly inhibit APOBEC3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation. J Biol Chem 280(10):8765-8775
117. Santa-Marta M et al (2007) HIV-1 Vif protein blocks the cytidine deaminase activity of B-cell specific AID in E. coli by a similar mechanism of action. Mol Immunol 44(4):583-590
118. Sasada A et al (2005) APOBEC3G targets human T-cell leukemia virus type 1. Retrovirology 2 (1):32
119. Sawyer SL, Emerman M, Malik HS (2004) Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol 2(9):E275
120. Schafer A, Bogerd HP, Cullen BR (2004) Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology 328 (2):163-168
121. Schrofelbauer B, Chen D, Landau NR (2004) A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc Natl Acad Sci USA 101 (11):3927-3932
122. Schrofelbauer B et al (2005) Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases. J Virol 79(17):10978-10987
123. Schrofelbauer B et al (2006) Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J Virol 80(12):5984-5991
124. Schumacher AJ, Nissley DV, Harris RS (2005) APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast. Proc Natl Acad Sci USA 102(28):9854-9859
125. Schumacher AJ et al (2008) The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J Virol 82(6):2652-2660
126. Sheehy AM et al (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418(6898):646-650
127. Sheehy AM, Gaddis NC, Malim MH (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9(11):1404-1407
128. Shirakawa K et al (2008) Phosphorylation of APOBEC3G by protein kinase A regulates its interaction with HIV-1 Vif. Nat Struct Mol Biol 15(11):1184-1191
129. Simon JH, Malim MH (1996) The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J Virol 70(8):5297-5305
130. Simon JH et al (1998) Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat Med 4 (12):1397-1400
131. Simon V et al (2005) Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog 1(1):e6
132. Sodroski J et al (1986) Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions. Science 231(4745):1549-1553
133. Stanley BJ et al (2008) Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly. J Virol 82(17):8656-8663
134. Stenglein MD, Harris RS (2006) APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J Biol Chem 281(25):16837-16841
135. Stevenson M et al (1990) HIV-1 replication is controlled at the level of T cell activation and proviral integration. Embo J 9(5):1551-1560
136. Stewart SA et al (1997) Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest. J Virol 71(7):5579-5592
137. Stopak K et al (2003) HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 12(3):591-601
138. Stopak KS et al (2007) Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J Biol Chem 282 (6):3539-3546
139. Strebel K et al (1987) The HIV 'A' (sor) gene product is essential for virus infectivity. Nature 328 (6132):728-730
140. Suspene R et al (2004) APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res 32(8):2421-2429
141. Suspene R et al (2005) Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci USA 102(23):8321-8326
142. Svarovskaia ES et al (2004) Human apolipoprotein B mRNA-editing enzyme-catalytic polypep-tide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J Biol Chem 279(34):35822-35828
143. Tan L et al (2008) Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1. Faseb J 23(1):279-287
144. Tanaka Y et al (2006) Anti-viral protein APOBEC3G is induced by interferon-alpha stimulation in human hepatocytes. Biochem Biophys Res Commun 341(2):314-319
145. Teng B, Burant CF, Davidson NO (1993) Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science 260(5115):1816-1819
146. Tian C et al (2006) Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J Virol 80(6):3112-3115
147. Tian C et al (2007) Virion packaging determinants and reverse transcription of SRP RNA in HIV-1 particles. Nucleic Acids Res 35(21):7288-7302
148. Turelli P, Trono D (2005) Editing at the crossroad of innate and adaptive immunity. Science 307 (5712):1061-1065
149. Turelli P et al (2004a) Inhibition of hepatitis B virus replication by APOBEC3G. Science 303 (5665):1829
150. Turelli P, Vianin S, Trono D (2004b) The innate antiretroviral factor APOBEC3G does not affect human LINE-1 retrotransposition in a cell culture assay. J Biol Chem 279(42):43371-43373
151. Vartanian JP et al (2008) Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science 320(5873):230-233
152. von Schwedler U et al (1993) Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol 67(8):4945-4955
153. Wang T et al (2007a) 7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G. J Virol 81(23):13112-13124
154. Wang J et al (2007b) The Vif accessory protein alters the cell cycle of human immunodeficiency virus type 1 infected cells. Virology 359(2):243-252
155. Wang T et al (2008) Distinct viral determinants for the packaging of human cytidine deaminases APOBEC3G and APOBEC3C. Virology 377(1):71-79
156. Waterston RH et al (2002) Initial sequencing and comparative analysis of the mouse genome. Nature 420(6915):520-562
157. Watson AJ, Wilburn LM (1992) Inhibition of HIV infection of resting peripheral blood lymphocytes by nucleosides. AIDS Res Hum Retroviruses 8(7):1221-1227
158. Wiegand HL, Cullen BR (2007) Inhibition of alpharetrovirus replication by a range of human APOBEC3 proteins. J Virol 81(24):13694-13699
159. Wiegand HL et al (2004) A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. Embo J 23(12):2451-2458
160. Willetts KE et al (1999) DNA repair enzyme uracil DNA glycosylase is specifically incorporated into human immunodeficiency virus type 1 viral particles through a Vpr-independent mechanism. J Virol 73(2):1682-1688
161. Xiao Z et al (2007) Characterization of a novel cullin5 binding domain in HIV-1 Vif. J Mol Biol 373(3):541-550
162. Xu H et al (2004) A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc Natl Acad Sci USA 101(15):5652-5657
163. Yang X, Gabuzda D (1998) Mitogen-activated protein kinase phosphorylates and regulates the HIV-1 Vif protein. J Biol Chem 273(45):29879-29887
164. Yang X, Goncalves J, Gabuzda D (1996) Phosphorylation of Vif and its role in HIV-1 replication. J Biol Chem 271(17):10121-10129
165. Yang B et al (2007a) Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA. J Biol Chem 282(16):11667-11675
166. Yang Y et al (2007b) Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F. Virology 365(1):92-100
167. Yu X et al (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302(5647):1056-1060
168. Yu Q et al (2004a) APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J Biol Chem 279(51):53379-53386
169. Yu Q et al (2004b) Single-strand specificity of APOBEC3G accounts for minus-strand deamina-tion of the HIV genome. Nat Struct Mol Biol 11(5):435-442
170. Yu Y et al (2004c) Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev 18(23):2867-2872
171. Zennou V et al (2004) APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J Virol 78(21):12058-12061
172. Zhang J, Webb DM (2004) Rapid evolution of primate antiviral enzyme APOBEC3G. Hum Mol Genet 13(16):1785-1791
173. Zhang H et al (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424(6944):94-98
174. Zhang W et al (2008a) Conserved and non-conserved features of HIV-1 and SIVagm Vif mediated suppression of APOBEC3 cytidine deaminases. Cell Microbiol 10(8):1662-1675
175. Zhang W et al (2008b) Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins. PLoS ONE 3(12):e3963
176. Zhang W et al (2008c) Cytidine deaminase APOBEC3B interacts with heterogeneous nuclear ribonucleoprotein K and suppresses hepatitis B virus expression. Cell Microbiol 10(1):112-121
177. Zheng YH et al (2004) Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol 78(11):6073-6076